<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: To evaluate the role of <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mp ids='MP_0001845'>inflammation</z:mp> in the aetiology of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we examined the association of oxidised <z:chebi fb="15" ids="39026">LDL</z:chebi> (ox-<z:chebi fb="15" ids="39026">LDL</z:chebi>) and soluble intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (sICAM-1) levels with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> incidence over 9 years in the <z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> Risk in Communities Study </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: In a large, prospective, case-cohort design, ox-<z:chebi fb="15" ids="39026">LDL</z:chebi> and sICAM-1 were measured in stored plasma samples collected at baseline in stratified samples of 581 <z:mp ids='MP_0002055'>diabetes</z:mp> cases and 572 non-cases selected from 10,275 middle-aged men and women without prevalent <z:mp ids='MP_0002055'>diabetes</z:mp> at baseline </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Compared with non-cases, <z:mp ids='MP_0002055'>diabetes</z:mp> cases had significantly higher mean baseline levels of ox-<z:chebi fb="15" ids="39026">LDL</z:chebi> and sICAM-1 </plain></SENT>
<SENT sid="3" pm="."><plain>Elevated ox-<z:chebi fb="15" ids="39026">LDL</z:chebi> and sICAM-1 were both associated with increased risk of incident <z:mp ids='MP_0002055'>diabetes</z:mp> after adjustment for age, sex, race and centre, with hazard ratios for the highest vs lowest tertiles of 1.68 (95% CI 1.25-2.24) and 1.91 (95% CI 1.45-2.50), respectively </plain></SENT>
<SENT sid="4" pm="."><plain>After additional adjustment for fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>, waist circumference, <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi>, triacylglycerol, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and C-reactive protein, only sICAM-1 remained an independent predictor of incident <z:mp ids='MP_0002055'>diabetes</z:mp> (hazard ratio 1.50; 95% CI 1.02-2.23) </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS/INTERPRETATION: In this community-based cohort of middle-aged US adults, elevated plasma ox-<z:chebi fb="15" ids="39026">LDL</z:chebi> and sICAM-1 levels were associated with increased risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Measurement of ICAM-1 or ox-<z:chebi fb="15" ids="39026">LDL</z:chebi>, or other measures related to <z:mp ids='MP_0001845'>inflammation</z:mp> or <z:mp ids='MP_0003674'>oxidative stress</z:mp>, may be helpful in identifying those patient populations in which to test whether novel therapies that inhibit specific pathways related to <z:mp ids='MP_0001845'>inflammation</z:mp> or <z:mp ids='MP_0003674'>oxidative stress</z:mp> are beneficial in the prevention of <z:mp ids='MP_0002055'>diabetes</z:mp> in humans </plain></SENT>
</text></document>